# ai-case-study

## Overview and Origin

### Novartis

  Novartis, Incorporated in 1996. The company was founded as a result of the merger of Sandoz and Ciba-Geigy.
The driving force behind the merger was to create a vision of accelerating innovation and asserting an even stronger position on the global markets.
Novartis AG is a publicly traded Swiss holding company; therefore it's primary source of funding is through the selling of shares 
on the stock exchange market.

## Business Activities

Novartis is a pharmaceutical company, that is utilizing emerging technologies such as Artificial Intelligence "AI" to innovate and reinvigorate medicine. This is intended to enable healthcare professionals provide better care for their patients; while also providing targeted options to patients.
  
According to the company's website; *Our medicines reach more than 250 million people worldwide* - Novartis

## Landscape

Being an innovator in the pharmaceutical industry, Novartis is leveraging Artificial Intelligence to analyze, accelerate, and discover insights into new medication. The ability to combine AI and health sciences practices (chemistry, Immunotherapy etc.) has proven to accelerate potential drug candidates; targeted pharmaceuticals and improve the efficacy of therapeutics. Novartis's major competitors are:
1. AstraZeneca
2. Pfizer
3. Bayer
4. Merck
5. Benevolent AI
6. Deep Genomics
7. Recursion Pharmaceuticals

## Results
Utilizing AI has increased Novartis drug discovery efforts while boosting efficiency. While quantifying the total impact AI might still be in it's early stages, the efforts and collaboration
is yielding promising results.

## Recommendations
As Stated above, the AI applications within the pharmaceutical industry is still in the early stages; collaboration  will be key. And Novartis is leading the way by collaborating with some research 
institutions. Of note, is it's collaboration with the University of California, Berkeley. This idea could potentially be expanded to include joint ventures with other pharmaceutical companies or better 
yet technology / Bio-technology companies that might have expertise in artifical intellegence.

## Links
<https://biopharmaapac.com/news/32/4116/revolutionizing-drug-discovery-15-ai-companies-to-watch-in-2024.html>
<https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality>
<https://www.pharmaceuticalprocessingworld.com/ai-pharma-drug-development-billion-opportunity/>
<https://www.strategyand.pwc.com/de/en/industries/pharma-life-science/re-inventing-pharma-with-artificial-intelligence.html>
<https://www.forbes.com/sites/cindygordon/2024/02/23/using-ai-to-modernize-drug-development-and-lessons-learned/?sh=4f61a65928e8>
<https://www.fda.gov/science-research/science-and-research-special-topics/artificial-intelligence-and-machine-learning-aiml-drug-development>

